Here's an article from the LA Times that was published June 1st...
Still no "Magic Bullet" weight loss drug
Snippets from the above article pertaining to Acomplia:
Quote:
A drug that would make weight loss easier is one of the most prized, but elusive, goals in medicine. And numerous pharmaceutical companies are working on diet drugs that could reach the market during the next decade. One company, Sanofi-Aventis, recently applied to the Food and Drug Administration for approval of a drug called Acomplia, which, if approved, would become the first new prescription obesity drug in six years.
But one thing is becoming painfully clear to researchers and drug companies: Previous efforts to produce a blockbuster diet drug have fizzled, and there is still no miracle remedy in sight. Recent studies of Acomplia (also known as rimonabant, its generic name) show that the drug, while potentially helpful, will not benefit everyone, and it will not produce substantial weight loss in most people.
Instead, Acomplia's role more likely would be as one of a number of diet drugs that not only aid weight loss but also address the medical consequences of obesity, such as diabetes and heart disease, say researchers. It's likely that a combination, or cocktail, of obesity drugs will ultimately prove most beneficial.
and
Quote:
As an obesity treatment, Acomplia may be best suited for people who are not only overweight but also have metabolic syndrome. Metabolic syndrome is a collection of symptoms, including high blood pressure, high cholesterol, large waist circumference, obesity and insulin resistance, that can lead to diabetes and heart disease without treatment.
A study published in April in the Lancet, a medical journal, showed that 67 percent of people taking 20 milligrams of Acomplia achieved an overall weight loss of 5 percent after one year, and 39 percent of the participants achieved a 10 percent weight loss.
Acomplia also produced an average reduction of 1.6 inches in waist circumference and led to improvements in cholesterol levels (including HDL, or "good" cholesterol) and insulin resistance...
Overall, half of the patients with metabolic syndrome no longer had the condition after taking Acomplia for two years...
But the drug has been found to have some significant side effects that could lower the odds of FDA approval. About 19 percent of the patients dropped out of the study due to depression, vomiting and nausea. Because of the possibility of a psychiatric side effect -- and because Acomplia is the first medication to act on the cannabinoid system in the brain -- the FDA may proceed with extra caution.
(this is a really interesting article BTW!)